Charles Catherine H, Luo Guang X, Kohlstaedt Lori A, Morantte Ianessa G, Gorfain Elliott, Cao Linguang, Williams Jimmy H, Fang Fang
Perlan Therapeutics, San Diego, California, USA.
Antimicrob Agents Chemother. 2003 May;47(5):1503-8. doi: 10.1128/AAC.47.5.1503-1508.2003.
We have developed a technology for improving avidity by making bivalent, trivalent, or tetravalent recombinant polypeptides. We designed tripartite proteins consisting of the Fab fragment of an antibody fused with a hinge derived from human immunoglobulin D that was further linked to polymerization domains derived from human coiled-coil proteins. We report here on the application of this method with a Fab domain directed against the major human rhinovirus receptor, intercellular adhesion molecule 1 (ICAM-1). Multivalent anti-ICAM-1 molecules were produced in bacteria and purified as soluble preassembled homogeneous proteins at high yield. These proteins successfully blocked rhinovirus infection in vitro, with the efficiency increasing from monomer to dimer, trimer, and tetramer. The diminished dissociation rate of these multivalent antibodies and their improved efficacy in preventing rhinovirus infection provide a foundation for producing prophylactic and therapeutic molecules against human rhinovirus, the causative agent of the majority of common colds.
我们已经开发出一种通过制备二价、三价或四价重组多肽来提高亲和力的技术。我们设计了一种三联体蛋白,它由抗体的Fab片段与源自人免疫球蛋白D的铰链区融合而成,该铰链区进一步与源自人卷曲螺旋蛋白的聚合结构域相连。我们在此报告该方法针对主要人类鼻病毒受体细胞间粘附分子1(ICAM-1)的Fab结构域的应用。多价抗ICAM-1分子在细菌中产生,并以高产率作为可溶性预组装的均质蛋白进行纯化。这些蛋白在体外成功阻断了鼻病毒感染,其效率从单体到二聚体、三聚体和四聚体逐渐提高。这些多价抗体解离速率的降低及其在预防鼻病毒感染方面提高的功效为生产针对人类鼻病毒(大多数普通感冒的病原体)的预防和治疗分子奠定了基础。